Phase 3
N=123
Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations
Meningitis · Meningococcal Infection
Bottom Line
View on ClinicalTrials.gov: NCT01359449 ↗Enrolled (actual)
123
Serious AEs
2.4%
Results posted
May 2013
Primary outcome: Primary: Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age. — NA; 4.34; 1740; 4.35 Titers
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® (Biological); Meningococcal Group C Conjugate vaccine: MenC (Biological)
- Age
- Pediatric · 0+ yrs
- Sex
- All
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Primary completion
- Jul 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Geometric Mean Titers of Serum Bovine Albumin Baby Rabbit Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age. |
NA; 4.34; 1740; 4.35; NA; 71.0 | — |
| PRIMARY Number of Participants With Serum Bovine Albumin Baby Rabbit Titers of ≥ 1:8 Following Vaccination With Either a Dose of Menactra Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age. |
NA; 1; 51; 2; NA; 40 | — |
| SECONDARY Geometric Mean Titers of Serum Bovine Albumin Human Complement Titers Following Vaccination With Either One Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age. |
NA; 2.23; 71.7; 2.21; NA; 17.4 | — |
| SECONDARY Number of Participants With Serum Bovine Albumin Human Complement Titers of ≥ 1:8 Following Vaccination With Either a Dose of Menactra® Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate® Vaccine at 12 Months of Age. |
NA; 1; 48; 1; NA; 39 | — |
| SECONDARY Geometric Mean Titers of Antibodies to Pediacel® Vaccine Antigens in Participants That Received a Dose of Menactra® at 12 and 18 Months of Age, Respectively, and a Booster Dose of Pediacel® Vaccine at 18 Months of Age. |
0.420; NA; 7.81; NA; 0.485; NA | — |
| SECONDARY Summary of Participants With Booster Response for Pediacel® Vaccine Antigens After Vaccination With Pediacel® Vaccine (Menactra Vaccine Group) |
44; NA; 43; NA; 38; NA | — |
| SECONDARY Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With Either a Dose of Menactra Vaccine at 12 and 18 Months of Age, Respectively, or One Single Dose of Menjugate Vaccine at 12 Months of Age |
21; 21; 0; 0; 26; 23 | — |
| SECONDARY Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Vaccination With a Second Dose of Menactra Vaccine at 18 Months of Age |
30; NA; 2; NA; 19; NA | — |
| SECONDARY Number of Participants Reporting at Least One Solicited Injection Site or Systemic Reaction Following Any of the Study Vaccination |
36; 21; 32; 23; 18; 8 | — |
Summary
The purpose for this study is to demonstrate the safety and immunogenicity of two doses of Menactra® administered between 12 and 18 months of age and concomitantly with routine immunization with two different provincial schedule
Primary Objectives:
* To describe the immunogenicity of Menactra® administered concomitantly with routine immunizations at 12 and 18 months in naïve or Menjugate-primed (MenC-primed) infants (measured by serum bactericidal assay using baby rabbit complement [SBA-BR])
* To describe the immunogenicity of MenC administered concomitantly with routine immunizations at 12 months of age (measured by SBA-BR)
Secondary Objectives:
Safety
* To describe the safety profile of Menactra® and MenC vaccines after each dose when given concomitantly with routine immunization.
Immunogenicity
* To describe the immunogenicity of both vaccines using serum bactericidal assay using human complement [SBA-HC]
* To describe the immunogenicity of Pediacel administered at 18 months.
Eligibility Criteria
Inclusion Criteria
- Aged 12 months (365 to 400 days) on the day of inclusion
- Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg
- Informed consent form has been signed and dated by the parent(s) or other legally authorized representative
- Subject and parent/legal representative are able to attend all scheduled visits and to comply with all trial procedures
- Group 1: Subject has received 3 primary vaccination doses of Pediacel as per routine immunization schedule
- Group 3: Subject has received two doses of MenC vaccine at approximately 2 and 4 months of age as per Alberta immunization schedule.
Exclusion Criteria
- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
- Planned participation in another clinical trial during the present trial period
- Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for influenza vaccination(s), which may be received at least two weeks before study vaccines
- Planned receipt of any vaccine in the 4 weeks following any trial vaccination
- Previous vaccination against Meningococcal disease OR
- Subject has previously received only one dose of MenC vaccine, or more than two doses of MenC vaccine, or two doses of MenC vaccine with the most recent dose received in the past 6 months
- Receipt of blood or blood-derived products in the past 3 months which might interfere with assessment of the immune response
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- Personal or maternal seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, as reported by the parent/legal representative
- History of documented invasive meningococcal disease
- At high risk for meningococcal disease during the trial
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
- History of contraindication to receipt of pertussis-containing vaccine
- Thrombocytopenia, as reported by the parent/legal representative, contraindicating intramuscular vaccination
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
- History of seizures
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- History of Guillain-Barré Syndrome.
Data sourced from ClinicalTrials.gov (NCT01359449). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.